Compugen Ltd. to Highlight Company’s Therapeutic Platforms at BioMed Israel 2008
May 26, 2008
TEL AVIV, ISRAEL, May 27, 2008
– Compugen Ltd. (NASDAQ: CGEN) today announced that Dr. Yossi Cohen, Compugen’s Vice President of Research and Development will present the company’s therapeutic activities at the BioMed Israel 2008 Conference on May 28 at 12:20 PM.In his presentation, Dr. Cohen will highlight five Compugen therapeutic discovery platforms and provide for each an example of an initial product candidate discovered through its use. These five therapeutic discovery platforms have been designed to predict and validate multiple novel product candidates in the form of peptide ligands for GPCRs, peptides that block disease associated confirmations of proteins, splice variant therapeutic proteins, new indications for known drugs, and targets for monoclonal antibody therapeutics.
Compugen’s mission is to be the world leader in the discovery and licensing of product candidates to the drug and diagnostic industries under milestone and revenue sharing agreements. The Company’s increasing inventory of powerful and proprietary discovery platforms is enabling the predictive discovery – field after field – of numerous therapeutic and diagnostic product candidates. These discovery platforms are based on the Company’s decade-long focus on the predictive understanding of important biological phenomena at the molecular level. Compugen’s current collaborations include Biosite, Medarex, Inc., Merck & Co., Inc., Ortho-Clinical Diagnostics (a Johnson & Johnson company), Roche, Siemens Healthcare Diagnostics, Inc., and Teva Pharmaceutical Industries. In 2002, Compugen established an affiliate – Evogene Ltd. (TASE: EVGN.TA) – to utilize the Company’s in-silico
predictive discovery capabilities in the agricultural biotechnology field.For additional information, please visit Compugen’s corporate Website at www.cgen.com
and Evogene’s corporate Website at www.evogene.com
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as“may”, “expects”, “anticipates”, “believes”, and “intends”, and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are identified and more fully explained under the heading “Risk Factors” in Compugen’s annual reports filed with the Securities and Exchange Commission.
Dikla Czaczkes AxselbardActing
Chief Financial Officer